Teva Pharmaceutical Industries Ltd (XBUL:TEV)
лв 15.85 0 (0%) Market Cap: 17.96 Bil Enterprise Value: 48.53 Bil PE Ratio: 0 PB Ratio: 4.12 GF Score: 44/100

Teva Pharmaceutical Industries Ltd at JPMorgan Healthcare Conference Transcript

Jan 13, 2020 / 06:30PM GMT
Christopher Thomas Schott
JP Morgan Chase & Co, Research Division - Senior Analyst

Good morning, everybody. I'm Chris Schott from JPMorgan, and it's my pleasure to be introducing Teva today. From the company, we have KÃ¥re Schultz, the company's President and CEO. After Chorus presentation, we're going to go to a breakout session, which is in the Olympic Room around the corner. And with that, I'll turn it over to KÃ¥re.

KÃ;re Schultz
Teva Pharmaceutical Industries Limited - President, CEO & Director

Â¥ -

Good morning, everybody. It's a pleasure to be here. We will be talking about the future. And in that connection, I will recommend you to take a look at this. I won't go through it. So we'll move to the next slide.

Now it's a real pleasure to be here. It's -- 2 years ago that I was here for the first time as CEO of Teva, and I can see a few of you that were there. And back then, we had a pretty dramatic situation. We had a debt of $34 billion. We had CoPaxone that have gone off-patent and had generic competition in the U.S., and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot